Literature DB >> 18321570

Fasting glucose improvement under dasatinib treatment in an accelerated phase chronic myeloid leukemia patient unresponsive to imatinib and nilotinib.

M Breccia, M Muscaritoli, L Cannella, C Stefanizzi, A Frustaci, G Alimena.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18321570     DOI： 10.1016/j.leukres.2008.01.015

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


× No keyword cloud information.
  16 in total

1.  Saturated fatty acids induce c-Src clustering within membrane subdomains, leading to JNK activation.

Authors:  Ryan G Holzer; Eek-Joong Park; Ning Li; Helen Tran; Monica Chen; Crystal Choi; Giovanni Solinas; Michael Karin
Journal:  Cell       Date:  2011-09-30       Impact factor: 41.582

2.  Antidiabetic Effects of the Senolytic Agent Dasatinib.

Authors:  Omid Salaami; Chia-Ling Kuo; Matthew T Drake; George A Kuchel; James L Kirkland; Robert J Pignolo
Journal:  Mayo Clin Proc       Date:  2021-11-09       Impact factor: 7.616

3.  Sorafenib decreases glycemia by impairing hepatic glucose metabolism.

Authors:  Jingjing Ma; Fang Sui; Yan Liu; Mengmeng Yuan; Hui Dang; Rui Liu; Bingyin Shi; Peng Hou
Journal:  Endocrine       Date:  2022-10-07       Impact factor: 3.925

Review 4.  Clinical review: kinase inhibitors: adverse effects related to the endocrine system.

Authors:  Maya B Lodish
Journal:  J Clin Endocrinol Metab       Date:  2013-02-28       Impact factor: 5.958

5.  Pharmacovigilance evaluation of the relationship between impaired glucose metabolism and BCR-ABL inhibitor use by using an adverse drug event reporting database.

Authors:  Naoto Okada; Takahiro Niimura; Yoshito Zamami; Hirofumi Hamano; Shunsuke Ishida; Mitsuhiro Goda; Kenshi Takechi; Masayuki Chuma; Masaki Imanishi; Keisuke Ishizawa
Journal:  Cancer Med       Date:  2018-12-18       Impact factor: 4.452

6.  Effects of Imatinib Mesylate (Gleevec) on human islet NF-kappaB activation and chemokine production in vitro.

Authors:  Dariush Mokhtari; Tingting Li; Tao Lu; Nils Welsh
Journal:  PLoS One       Date:  2011-09-14       Impact factor: 3.240

7.  The clinically approved drugs dasatinib and bosutinib induce anti-inflammatory macrophages by inhibiting the salt-inducible kinases.

Authors:  James Ozanne; Alan R Prescott; Kristopher Clark
Journal:  Biochem J       Date:  2015-01-15       Impact factor: 3.857

8.  Effects of first- and second-generation tyrosine kinase inhibitor therapy on glucose and lipid metabolism in chronic myeloid leukemia patients: a real clinical problem?

Authors:  Alessandra Iurlo; Emanuela Orsi; Daniele Cattaneo; Veronica Resi; Cristina Bucelli; Nicola Orofino; Mariarita Sciumè; Chiara Elena; Valeria Grancini; Dario Consonni; Ester Maria Orlandi; Agostino Cortelezzi
Journal:  Oncotarget       Date:  2015-10-20

Review 9.  European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia.

Authors:  J L Steegmann; M Baccarani; M Breccia; L F Casado; V García-Gutiérrez; A Hochhaus; D-W Kim; T D Kim; H J Khoury; P Le Coutre; J Mayer; D Milojkovic; K Porkka; D Rea; G Rosti; S Saussele; R Hehlmann; R E Clark
Journal:  Leukemia       Date:  2016-04-28       Impact factor: 11.528

10.  Nilotinib exacerbates diabetes mellitus by decreasing secretion of endogenous insulin.

Authors:  Yoshikiyo Ito; Toshihiro Miyamoto; Yong Chong; Toshinobu Maki; Koichi Akashi; Tomohiko Kamimura
Journal:  Int J Hematol       Date:  2012-11-23       Impact factor: 2.490
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.